Media.Player

A-16 RFP: a Novel Biomarker for Cancer

Technology Benefits

ΓùÅ Effective: This agent will assist the effectiveness of known anti-cancer drugsΓùÅ Safe: Combination use of this agent will reduce the amount of anti-cancer drugsΓùÅ Assistance: This agent will assist the decisions for treatment method

Technology Application

ΓùÅ Therapeutic antibody drug for cancer patientsΓùÅ Gene/Protein Biomarker for cancer prognosisΓùÅ Anti-RFP antibody can be used as a research tool for lab technicians

Detailed Technology Description

None

Supplementary Information

Patent Number: WO2010023917A1
Application Number: WO2009JP4162A
Inventor: TAKAHASHI, Masahide | KATO, Takuya | KIKKAWA, Fumitaka
Priority Date: 1 Sep 2008
Priority Number: WO2010023917A1
Application Date: 27 Aug 2009
Publication Date: 4 Mar 2010
IPC Current: A61K004500 | A61K00317105 | A61K0031711 | A61K0031713 | A61K003843 | A61K004506 | A61K004800 | A61P003500 | A61P003502 | A61P004300 | C12N001509 | C12Q000168 | G01N003348 | G01N003353
Assignee Applicant: National University Corporation Nagoya University
Title: POTENTIATOR OF ACTIVITY OF ANTI-CANCER AGENT AND USE THEREOF, AND BIOMARKER FOR PREDICTION OF PROGNOSIS IN CANCER PATIENT AND USE THEREOF | POTENTIALISATEUR DE L'ACTIVITÉ D'UN AGENT ANTICANCÉREUX ET SON UTILISATION, ET BIOMARQUEUR PERMETTANT D'ÉMETTRE UN
Usefulness: POTENTIATOR OF ACTIVITY OF ANTI-CANCER AGENT AND USE THEREOF, AND BIOMARKER FOR PREDICTION OF PROGNOSIS IN CANCER PATIENT AND USE THEREOF | POTENTIALISATEUR DE L'ACTIVITÉ D'UN AGENT ANTICANCÉREUX ET SON UTILISATION, ET BIOMARQUEUR PERMETTANT D'ÉMETTRE UN PRONOSTIC CONCERNANT UN PATIENT CANCÉREUX ET SON UTILISATION
Summary: The potentiator is useful for enhancing activity of agent for treating cancer, e.g. colon cancer and endometrial cancer (all claimed) in mammal e.g. mouse, rat, cow, pig, cat and human.
Novelty: Activity potentiator of agent for treating cancer, e.g. colon cancer and endometrial cancer, comprises compound capable of inhibiting expression of RET finger protein gene or its activity as active ingredient

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

Researchers at Nagoya University have identified a novel agent which will overcome the treatment failure of drug resistant cancers. Previously, it has been reported that many anti-cancer drugs generate a synergistic effect with histone deacetylase. NU researchers have identified that RFP (RET finger protein) controlled by histone deacetylase promotes resistance to oxidative stress in cancer cells. By inhibiting the expression of RFP, the cancer cells restored sensitivity to anti-cancer drugs. On the other hand, it has been shown that gene and protein expression level of RFP correlates to poor clinical outcomes in colon cancer and ovarian cancer patients. This suggests that RFP level examination using a biomarker will assist doctors to make decisions on their patient treatment courses.

*Principal Investigator

Name: Masahide Takahashi MD, PhD, Professor

Department: Department of Tumor Pathology at Graduate School of Medicine, Nagoya University

Country/Region

USA